5s japan WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company’s determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months. Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio commented, "We remain steadfast in our mission to advance medical science, however as CEO of the company, preservation of shareholder value remains a priority. We urge all stakeholders to consider the profound impact short selling innovative healthcare companies has on lifesaving therapies. While stock price fluctuations are part of the public market dynamics, Tevogen Bio is acutely aware of the undue influence short sellers have.” William Keane, VP of Strategic Initiatives, and graduate of the FBI National Academy stated, “We are aware and monitoring the actions of potential short selling activity targeting our company. We will continue to bring light to this situation and will work with the appropriate authorities as needed.” The company plans to provide further updates on its progress in the coming weeks. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com

California 74, Arizona 62

Heat earns gusty road win over Rockets behind another excellent night from Tyler Herro

NoneChampionship roundup: Leeds return to top, Portsmouth game hit by power cut

The Philadelphia Eagles listed three players on their initial injury report ahead of their Week 13 matchup against the Baltimore Ravens. The Ravens listed seven players on their initial injury report. Here's the Eagles-Ravens injury report, with analysis... Wednesday notes : • Smith did not play Week 12, but it didn't matter as Saquon Barkley ran all over the Rams. The Ravens are allowing 277.7 passing yards per game, second-worst in the NFL, so this is a game that the Eagles really need Smith to help exploit a Baltimore defensive weakness. • Slay suffered a concussion Week 12 against the Rams. He was replaced in the lineup by Isaiah Rodgers, who gave up a few completions, but also made one of the plays of the night when he forced a red zone fumble that was recovered by the Eagles. • Ringo did not play at all on defense Week 12 despite some garbage time opportunities late in the game. He likely got hurt earlier in the game. • Not shown above are Saquon Barkley, Mekhi Becton, London Dickerson, Lane Johnson, Cam Jurgens, Jordan Mailata, and Josh Sweat, who were all limited with "rest" days. Other notable players on IR, PUP, suspension, etc. • EDGE Brandon Graham (IR) : Graham tore his left triceps in the Eagles' win over the Rams. Before the season, Graham said that the 2024 season, his 15th in the NFL, would be his last. He played very well, and was arguably the team's best edge defender. If indeed his season is over, Graham will have finished with 20 tackles and 3.5 sacks, with his stats not truly showing his actual impact, as has been the case throughout his career. • S James Bradberry (IR) : The Eagles kept Bradberry on their active roster for no good reason at 53-man cutdowns, and then the next day he suffered a "lower body" injury that was originally supposed to keep him out 6-8 weeks. MORE : NFC Hierarchy/Obituary: Week 13 edition Wednesday notes : • The Ravens held a walkthrough, so this is just an estimation. • Roquan Smith is the Ravens' first-team All-Pro linebacker. On the season he has 110 tackles. He did not play Week 12 against the Chargers, but his projected ability to practice on Wednesday in a step in the direction of being able to play again, I guess? He did not practice at all last week. • Van Noy is in his 12th season. He co-leads the Ravens with 8 sacks. • Kolar has 9 catches for 131 yards and a TD this season. He has a broken arm and is out. He'll likely go on IR later in the week. • Maulet is a journeyman slot corner. Backup. Other notable players on IR, PUP, suspension, etc. • DT Michael Pierce : Rotational DT. 15 tackles, 1 sack this season. He had his 21-day practice window opened on Wednesday. • RS Deonte Harty : Ultra-small (5'6, 170) return specialist. MORE : Eagles film review: Josh Sweat is having a bounce-back season Follow Jimmy & PhillyVoice on Twitter: @JimmyKempski | thePhillyVoice Like us on Facebook: PhillyVoice Sports Add Jimmy's RSS feed to your feed readerLIVERPOOL, England (AP) — Real Madrid midfielder Eduardo Camavinga was injured and substituted off in the second half of his team's 2-0 loss to Liverpool in the Champions League on Wednesday. The France international pulled up sharply as he chased the ball and fell to ground, holding the back of his left leg after appearing to hurt his hamstring. He was briefly treated by Madrid's medical staff before instructions were sent to the bench to bring on a replacement and Dani Ceballos came on as a substitute in the 57th minute at Anfield. Camavinga was able to walk off the field but limped as he made his way to the locker room. The 22-year-old Camavinga sustained knee injuries last season that ruled him out for long periods of the campaign. The loss left Madrid in danger of being eliminated at the first phase of the new-look Champions League. The defending champion is 24th in the standings, which is the last playoff spot for the round of 16, with the top eight advancing automatically. AP soccer: https://apnews.com/hub/soccer

ITV I'm A Celebrity's Coleen Rooney takes swipe at Wayne as she opens up about struggles

Michigan aims to cap lost season by beating Ohio StateF1 expands grid, adds Cadillac brand and new American team for '26

Dublin Fingal West General Election 2024 updates: ‘I've lost my seat, and that's very disappointing’ – Minister Joe O’Brien

Dana Announces Leadership Transition and Actions to Accelerate Value Creation